Company Filing History:
1 out of 73 
1 out of 1,591 
1 out of 17 
Years Active: 2025
Title: Scott Raskin: Innovator in Cancer Treatment
Introduction
Scott Raskin is a notable inventor based in Silver Spring, MD (US). He has made significant contributions to the field of cancer treatment through his innovative research and patented technologies. His work focuses on developing methods and compositions that target cancer cells, particularly those expressing the SSX2 peptide.
Latest Patents
Scott Raskin holds a patent for "Methods and composition for a binding molecule targeting cancer cells expressing SSX2 peptide 41-49 in HLA-A*0201 context." This patent discloses binding molecules related to Synovial Sarcoma X breakpoint 2 and outlines methods for their use in the detection and treatment of cancer. His innovative approach aims to improve the accuracy and effectiveness of cancer therapies.
Career Highlights
Throughout his career, Scott has worked with prestigious institutions such as Children's National Medical Center and Washington University. His experience in these organizations has allowed him to collaborate with leading experts in the field and contribute to groundbreaking research in cancer treatment.
Collaborations
Scott Raskin has collaborated with notable colleagues, including Eric Yvon and Catherine M. Bollard. These partnerships have enhanced his research efforts and expanded the impact of his work in the medical community.
Conclusion
Scott Raskin's contributions to cancer treatment through his innovative patents and collaborations highlight his dedication to improving patient outcomes. His work continues to inspire advancements in the field of oncology.